Skip Navigation


JAC Advance Access originally published online on May 4, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):944-949; doi:10.1093/jac/dki134
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/944    most recent
dki134v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brown, S. D.
Right arrow Articles by Traczewski, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, S. D.
Right arrow Articles by Traczewski, M. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control

Steven D. Brown* and Maria M. Traczewski

The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070, USA

* Corresponding author. Tel: +1-503-682-3232; Fax: +1-503-682-2065; Email: sbrown{at}clinmicroinst.com

Objectives: To determine the spectrum of activity of doripenem and to propose tentative MIC and disc diffusion breakpoints.

Methods: The in vitro susceptibilities of 2137 bacterial isolates, representing 28 different species, to doripenem, imipenem and meropenem were determined by the NCCLS broth microdilution and disc diffusion testing methods.

Results: The doripenem MIC50s/90s were (in mg/L) for Enterobacteriaceae, 0.06/0.25; Pseudomonas aeruginosa, 0.25/1; Haemophilus influenzae, 0.12/0.5; streptococci, 0.016/0.5 and for staphylococci, 0.06/4. Like other carbapenems tested, doripenem MIC50s/90s were >32/>32 and 0.5/32 mg/L for the enterococci and non-fermentative Gram-negative bacilli (excluding P. aeruginosa), respectively. Against members of the Enterobacteriaceae and H. influenzae, doripenem was generally more active than imipenem and the same as or slightly less active than meropenem. Values for the non-fermentative Gram-negative bacilli excluding P. aeruginosa were comparable for all three carbapenems. Doripenem MICs increased with increasing resistance to methicillin (staphylococci), penicillin (streptococci) and strains that were ß-lactamase-negative ampicillin-resistant (Haemophilus). Doripenem exhibits excellent activity against extended-spectrum ß-lactamase-producing strains of Escherichia coli and Klebsiella spp. The NCCLS disc diffusion test was performed simultaneously on all organisms.

Conclusions: Assuming the MIC susceptible breakpoints for doripenem are ≤1 mg/L for the streptococci and ≤2 mg/L for all other genera, then disc diffusion zone diameter breakpoints can be proposed. In addition, MIC and/or disc diffusion quality control ranges of doripenem were determined for 10 ATCC reference strains.

Keywords: spectrum , QC , breakpoints


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
P. D. Lister, D. J. Wolter, and N. D. Hanson
Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
Clin. Microbiol. Rev., October 1, 2009; 22(4): 582 - 610.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. M. E. Wagenlehner, C. Wagenlehner, R. Redman, W. Weidner, and K. G. Naber
Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1567 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Pillar, M. K. Torres, N. P. Brown, D. Shah, and D. F. Sahm
In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4388 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. F. J. Brown, R. Hope, D. M. Livermore, G. Brick, K. Broughton, R. C. George, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc
Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06
J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii75 - ii85.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. A. Davies, W. Shang, K. Bush, and R. K. Flamm
Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1510 - 1512.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Cerquetti, M. Giufre, R. Cardines, and P. Mastrantonio
First Characterization of Heterogeneous Resistance to Imipenem in Invasive Nontypeable Haemophilus influenzae Isolates
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3155 - 3161.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Turnidge and G. Bordash
Statistical Methods for Establishing Quality Control Ranges for Antibacterial Agents in Clinical and Laboratory Standards Institute Susceptibility Testing
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2483 - 2488.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.